3D-printing method produces living tissue for regenerative medicine

Researchers from the University of Oxford have developed a new 3D-printing method to improve how laboratory-grown cells form living structures. Explained in Scientific Reports, the new method aims to change regenerative medicine by producing complex tissues and cartilage capable of supporting or repairing damaged areas in the body.

This study described a new method of additive printing, led by Hagan Bayley, professor of chemical biology in Oxford University, that allows cells to mimic or enhance natural tissue.

“We were aiming to fabricate 3D living tissues that could display the basic behaviors and physiology found in natural organisms,” said Alexander Graham, lead author and 3D booprinting scientist at OxSyBio (Oxford Synthetic Biology). “To date, there are limited examples of printed tissues, which have the complex cellular architecture of native tissues. Hence, we focused on designing a high-resolution cell printing platform, from relatively inexpensive components, that could be used to reproducibly produce artificial tissues with appropriate complexity from a range of cells including stem cells.”

Researchers used cells with protective nanoliter droplets wrapped in a lipid coating, layered on top of one another, to produce living structures. These printed tissues allow for the artificial tissue to mimic natural tissue. With further development, researchers believe the regenerative tissue could be used to reproduce human tissue models for clinical testing.

“The bioprinting approach developed with Oxford University is very exciting, as the cellular constructs can be printed efficiently at extremely high resolution with very little waste,” said Adam Perriman from the University of Bristol. “The ability to 3D print with adult stem cells and still have them differentiate was remarkable, and really shows the potential of this new methodology to impact regenerative medicine globally.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.